Hera BioLabs provides preclinical research services with a focus on gene editing. The company offers proprietary platforms and custom research models to support drug discovery and development.

Hera BioLabs

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Steven D. Schwartz

Thomas W. Chalberg

Mark S. Blumenkranz

Adverum Biotechnologies, Inc.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Hera BioLabs	Adverum Biotechnologies, Inc.	AstraZeneca PLC	bluebird bio, Inc.
Symbol		ADVM	AZN	BLUE
MSH ID	COM:HERABIOLABS	COM:ADVERUM	COM:ASTRAZENECA	COM:BLUEBIRDBIO
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Drug Manufacturers - General	Biotechnology
Country	US	US	GB	US
Stage	Venture Round
Employee Count		121	89.90K	323
Website	herabiolabs.com	adverum.com	astrazeneca.com	bluebirdbio.com
LinkedIn		adverum-biotechnologies	astrazeneca	bluebirdbio
Founders

Metric
Market Cap		161.49M	2.39B	200.45M
Enterprise Value
Monthly Web Traffic	1.41K		758.60K
Web Traffic Growth	-0.46		-0.13
Valuation
Raised Capital	1.07M

Metric
Revenue	45.81B	29.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	37.54B	-4.03M
EBITDA	13.91B	-167.16M
Operating Income	8.19B	-244.26M
Net Income	5.96B	-211.91M
EPS	3.84	-1.93
Diluted EPS	3.81	-1.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82	-0.10
Operating Profit Margin	0.19	-5.97
EBITDA Margin	0.30	-5.67
Net Profit Margin	0.13	-3.61
Return on Equity	0.17	-0.29
Return on Assets	0.06	-0.13
Return on Capital Employed	0.12	-0.30

HERA

COM:HERABIOLABS

Hera BioLabs

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.12	-1.26
P/B Ratio	5.41	0.44
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.51	12.15
EV Multiple	16.93	0.76

Metric
Days Sales Outstanding		386.42
Days Payables Outstanding	846.26	302.96
Days Inventory Outstanding	239.45	320.30
Operating Cycle	317.44	707.83
Cash Conversion Cycle	95.22	404.59
Asset Turnover	0.47	0.10

Metric
Operating Cash Flow	10.35B	-235.05M
Free Cash Flow	6.57B	-239.24M
Cash Flow to Debt	0.36	-0.54
Operating Cash Flow/Sales	0.23	-3.95
Free Cash Flow Yield	0.03	-1.26

Metric
Cash & Equivalents	5.84B	221.75M
Accounts Receivable		5.04M
Inventory	5.42B	22.92M
Goodwill	20.05B	5.65M
Debt to Capitalization	0.48	0.88
Debt to Assets	0.30	0.49
Current Ratio	0.79	1.55
Quick Ratio	0.70	1.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.73
R&D to Revenue	0.23	8.28
SG&A to Revenue